General MedicationsINTRAVENOUSStandard
IMJUDO
TREMELIMUMAB-ACTL
Standard Dose
25MG/1.25ML(20MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview IMJUDO is listed in Drugs@FDA under application 761289 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TREMELIMUMAB-ACTL Form and strength INJECTABLE;INTRAVENOUS - 25MG/1.25ML(20MG/ML) Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2024-07-24 00:00:00.
Structured Monograph
Clinical summary
Approval overview IMJUDO is listed in Drugs@FDA under application 761289 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient TREMELIMUMAB-ACTL Form and strength INJECTABLE;INTRAVENOUS - 25MG/1.25ML(20MG/ML) Sponsor ASTRAZENECA AB Submission history Latest submission status date: 2024-07-24 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.